glp-1 latest use tripled among non-diabetics, reaching $5.8B in 2022 use oral spray GLP-1 Advanced Intra-Oral Spray, by

Similar effects have been observed on eating control, sweet cravings, and symptoms of food addiction [147,[150], [151], [152], [153]]

GLP-1 receptor agonists (GLP-1 RAs) have shown promise in improving metabolic outcomes, but their specific effects on MAFLD remain unclear

The identification of a mechanistically informed acceptable and safe therapeutic capable of reducing craving, withdrawal, hyperphagia and post-cigarette smoking cessation weight gain would be potentially very impactful in subpopulations as well as the general population

Both can affect sulfur burp frequency and severity, though in different ways